Skip to main content
LUNG logo

LUNG · Pulmonx Corp

Track LUNG — free
$2.74 +0.05 (+1.86%)
Market Cap
$119.33M
Shares
43.55M
Volume · Nov 19 592.17K Avg daily vol (3M) 633.12K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.74 Open$2.73 Day$2.70–3.04 52W close$1.17–3.17 Avg vol 30d1.0M Short int788K · 1.8% of shares · 1.0d Short vol42% Last earningsOct 27, 2026 DataOct 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Mar 3, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 6.2% as net loss narrows 39.9%

Pulmonx Corp generated revenue of $22.8 million for the three months ended September 30, 2026, up 6.2%, while gross margin rose to 76.2% and net loss narrowed 39.9% to $8.4 million.

Revenue $22.84M ▲ 6.2% Net loss $8.39M Diluted EPS -$0.19
Read from the MD&A section
3 source passages
We generated revenue of $22.8 million, with a gross margin of 76.2% and a net loss of $8.4 million, for the three months ended September 30, 2026 compared to revenue of $21.5 million, with a gross margin of 74.7% and a net loss of $14.0 million, for the three months ended September 30, 2025. Revenue increased by $1.3 million, or 6.2%, to $22.8 million for the three months ended September 30, 2026, compared to $21.5 million for the three months ended September 30, 2025. | Net loss | (8,394) | (13,957) | 5,563 | (39.9)% | Open the document at this passage
Oct 27
Earnings call
Quarterly revenue returns to growth, rising 6% to $22.8 million

Worldwide revenue for the third quarter of 2026 was $22.8 million, a 6% increase from the prior year, and management called this a first return to global year-over-year growth. U.S. revenue rose 7% to $14.9 million, and full-year 2026 revenue guidance of $90 to $92 million was reiterated. Adjusted EBITDA loss fell nearly 60% to $3.5 million.

6 source passages
Total worldwide revenue in the third quarter of 2026 was $22.8 million, a 6% increase from $21.5 million in the same period last year This marks our first return to global year-over-year growth since Glenn and I rejoined the company last year. U.S. revenue in the third quarter was $14.9 million, a 7% increase from $14 million during the same period of the prior year. We are reiterating our expectation of full-year 2026 revenue in the range of $90 to $92 million. This nearly 60% reduction in adjusted EBITDA loss further demonstrates the progress we've made in realizing near-term operating leverage Adjusted EBITDA loss, which excludes non-cash stock-based compensation expense, for the third quarter of 2026 was $3.5 million compared to $8.2 million in the same period of the prior year. Open the document at this passage
Oct 27
Current report 8-K
Third-quarter revenue rises 6% to $22.8 million

Pulmonx reported third-quarter 2026 revenue of $22.8 million, a 6% increase over the same period last year, and returned to year-over-year growth. Net loss narrowed to $8.4 million, or $0.19 per share, from $14.0 million, or $0.34 per share, a year earlier. For full-year 2026, revenue is still expected to be in the range of $90 million to $92 million, with gross margin now expected at approximately 77%.

Financial results
5 source passages
Achieved worldwide revenue of $22.8 million in the third quarter of 2026, a 6% increase over the same period last year We are very pleased to have returned to year-over-year revenue growth in the third quarter. Net loss in the third quarter of 2026 was $8.4 million, or $0.19 per share, compared to a net loss of $14.0 million, or $0.34 per share, for the same period in 2025. Pulmonx continues to expect revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company now expects gross margin for the full year 2026 to be approximately 77%. Open the document at this passage
Aug 4
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $22.76M ▼ 4.6% Net loss $10.08M Diluted EPS -$0.24
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$88.78M
Trailing 12 months
Net income (TTM)
−$42.55M
Trailing 12 months
Revenue growth YoY
+6.2%
Year over year
Operating margin
-44.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-21.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$14.88M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.5%
Year over year · more shares
Price change (1Y)
+92.1%
Trailing year
Short interest
1.8%
Latest settlement · 1.0 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Oct 27, 2026
Q3 FY26

TL;DR. Pulmonx returned to Q3 revenue growth, improved gross margin and operating leverage, reiterated $90 million–$92 million revenue guidance, and expects approximately $22 million of 2026 cash burn, 30% below 2025. AeroSeal enrollment remains on track and China commercial activity has restarted, while nine-month revenue and losses remain headwinds and material AeroSeal European revenue is not expected until 2028.

Bullish
  • + Worldwide revenue returned to year-over-year growth in Q3 2026. new
  • + Gross margin improved and operating leverage reduced Q3 losses. new
  • + Management updated full-year gross-margin and operating-expense expectations while reiterating revenue guidance. new
  • + Cash burn is expected to decline substantially, and management sees a pathway to cash-flow break-even. new
  • + AeroSeal enrollment remains on track, and management believes it can expand the addressable market by roughly 20% globally. new
Bearish
  • − Nine-month worldwide revenue remained down 2.5% year over year. new
  • − International revenue growth was constrained by the absence of sales to the China distributor during the quarter. new
  • − Management did not provide 2027 guidance or a timeframe for sustaining double-digit growth. new
  • − AeroSeal's European launch is expected to be limited in 2027, with material revenue anticipated in 2028. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +59%
above
Price vs 50-day avg +25%
above
RSI (14) 57
neutral
MACD trend Negative
52-week position 79%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +46%
trailing
6-month return +72%
trailing
YTD return +24%
this year
Relative strength +78%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Distributing
-6% holders QoQ · +16 funds added
Insider flow Distributing
Net -$177.0K over 90 days · 100% sells
Short interest Rising
1.81% of shares out · ▲ +12.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
101 holders — near 3-yr low, contrarian setup
Squeeze score 53
elevated · 0–100
Fundamentals
Strong
Revenue growth +8%
Y/Y
Gross margin 74%
expanding
EPS growth +8%
Y/Y
Free cash flow $-32.8M
Balance sheet $32.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 96%
annualized · 1-yr
Max drawdown −55%
past year
ATR 9.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 7 of last 8
Latest guidance · from the 8-K filed Oct 27, 2026
Revenue · full year 2026 Maintained $90M – $92M
Jul 29, 2026 $90M – $92M changed to Oct 27, 2026 $90M – $92M
prior FY $90.5M midpoint +0.6% Y/Y
Gross margin · full year 2026 Raised 77%
Jul 29, 2026 76% changed to Oct 27, 2026 77%
Total operating expenses · full year 2026 Lowered $108M – $109M
Jul 29, 2026 $109M – $111M changed to Oct 27, 2026 $108M – $109M
Previous outlook earlier release · from the Earnings Call filed Jul 29, 2026

Still-open targets the latest release did not restate under the same label.

Cash burn · full year 2026 $23M
Guided vs delivered · last 8 settled
Total revenue full year 2025
guided $89M – $90M
$90.5M Beat +1.1%
Revenue full year 2024
guided $81M – $84M
$83.79M In line
Revenue full year 2023
guided $67M – $68M
$68.68M Beat +1.7%
Revenue full year 2022
guided $51.5M – $52.5M
$53.66M Beat +3.2%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+59% Bullish
Price vs 50-day avg
+25% Bullish
RSI (14)
57 Neutral
MACD trend
Negative Bearish
52-week position
79% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Distributing
-6% holders QoQ · +16 funds added
Insider flow Distributing
Net -$177.0K over 90 days · 100% sells
Short interest Rising
1.81% of shares out · ▲ +12.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
101 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1 Now $3 · 79% Range high $3
vs 200-day avg +59% vs 50-day avg +25%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA loss non-GAAP $5.1M the second quarter of 2026 —
Constant currency revenue change -6% the second quarter of 2026 —
Gross margin 78% the second quarter of 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LUNG
Pulmonx Corp
this stock
$119.33M +24.0% +8.0% — 1.8%
ABT
Abbott Laboratories
$179.90B -17.1% +5.7% 38.8 1.1%
MDT
Medtronic plc
$128.69B +4.7% +8.4% 24.8 1.8%
SYK
Stryker Corp
$119.19B -10.9% +11.2% 33.3 1.7%
BSX
Boston Scientific Corp
$62.31B -54.9% +12.5% 18.2 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
101
% held
61.1%
Net QoQ
+401.3K sh
Top holder
PRIMECAP MANAGEMENT CO/CA/
Held Float
View
Held by Funds
Fund positions
31
View
Short & Settlement
Short Interest Rising
Shares short
787.5K
Days to cover
1.0d
Change
+88.9K sh
View
Short Volume
Short vol %
42%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
6.2K
Value
$12.4K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
26.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$177.0K
Buyers / Sellers
0 / 4
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$90.5M
Net income (FY)
$-54.0M
EPS diluted
$-1.33
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 3, 2026
This year
15

Pulmonx Corp generated revenue of $22.8 million for the three months ended September 30, 2026, up 6.2%, while gross margin rose to 76.2% and net loss narrowed 39.9% to $8.4 million.

View
Proposed Sales
Value
$95.3K
Shares
48.9K
Filed
Jan 22, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 2, 2026
Last webcast
Nov 11, 2026
View
Investor Relations
Latest news
Pulmonx to Participate in the Pip…
Published
Nov 18, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
LUNG -8.7% +45.7% +72.3% -8.8% +24.0%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -3.2% +52.0% +78.0% -3.6% +19.0%
Key facts CIK 1127537 CUSIP 745848101 13F (30d) 114 filings 96 filers Visit website Investor relations